Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study
- PMID: 20003285
- PMCID: PMC3003532
- DOI: 10.1186/ar2878
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study
Abstract
Introduction: Cardiovascular disease (CVD) is a major cause of premature mortality among Systemic lupus erythematosus (SLE) patients. Many studies have measured and evaluated risk factors for premature subclinical atherosclerosis, but few studies are prospective and few have evaluated risk factors for hard endpoints, i.e. clinically important cardiovascular events (CVE). We investigated the impact of traditional and lupus associated risk factors for the first ever CVE in a longitudinal cohort of SLE patients.
Methods: A total of 182 SLE patients (mean age 43.9 years) selected to be free of CVE were included. Cardiovascular and autoimmune biomarkers were measured on samples collected after overnight fasting at baseline. Clinical information was collected at baseline and at follow up. End point was the first ever CVE (ischemic heart, cerebrovascular or peripheral vascular disease or death due to CVD). Impact of baseline characteristics/biomarkers on the risk of having a first CVE was evaluated with Cox regression.
Results: Follow up was 99.5% after a mean time of 8.3 years. Twenty-four patients (13%) had a first CVE. In age-adjusted Cox regression, any positive antiphospholipid antibody (aPL), elevated markers of endothelial activation (von Willebrand factor (vWf), soluble vascular cellular adhesion molecule-1 (sVCAM-1)) and fibrinogen predicted CVEs. Of SLE manifestations, arthritis, pleuritis and previous venous occlusion were positively associated with future CVEs while thrombocytopenia was negatively associated. Among traditional risk factors only age and smoking were significant predictors. In a multivariable Cox regression model age, any positive aPL, vWf and absence of thrombocytopenia were all predictors of the first CVE.
Conclusions: In addition to age, positive aPL, biomarkers indicating increased endothelial cell activity/damage, and absence of thrombocytopenia were independent predictors of CVEs in this prospective study. Our results indicate that activation of the endothelium and the coagulation system are important features in SLE related CVD. Furthermore, we observed that the risk of CVEs seems to differ between subgroups of SLE patients.
Comment in
-
Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge.Arthritis Res Ther. 2010;12(1):107. doi: 10.1186/ar2927. Epub 2010 Feb 22. Arthritis Res Ther. 2010. PMID: 20236499 Free PMC article.
Similar articles
-
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study.Arthritis Res Ther. 2012;14(2):R46. doi: 10.1186/ar3759. Arthritis Res Ther. 2012. PMID: 22390680 Free PMC article.
-
Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up.Semin Arthritis Rheum. 2023 Aug;61:152226. doi: 10.1016/j.semarthrit.2023.152226. Epub 2023 May 12. Semin Arthritis Rheum. 2023. PMID: 37201214
-
Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.Lupus. 2018 Apr;27(4):665-669. doi: 10.1177/0961203317734924. Epub 2017 Oct 19. Lupus. 2018. PMID: 29050535
-
Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.Autoimmun Rev. 2019 Nov;18(11):102395. doi: 10.1016/j.autrev.2019.102395. Epub 2019 Sep 11. Autoimmun Rev. 2019. PMID: 31520800
-
Systemic lupus erythematosus and cardiovascular disease.J Intern Med. 2023 Jan;293(1):48-62. doi: 10.1111/joim.13557. Epub 2022 Aug 18. J Intern Med. 2023. PMID: 35982610 Free PMC article. Review.
Cited by
-
Systemic lupus erythematosus and thrombosis.Thromb J. 2015 Apr 23;13:16. doi: 10.1186/s12959-015-0043-3. eCollection 2015. Thromb J. 2015. PMID: 25908929 Free PMC article.
-
Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus.Clin Rheumatol. 2012 Apr;31(4):669-75. doi: 10.1007/s10067-011-1910-3. Epub 2011 Dec 23. Clin Rheumatol. 2012. PMID: 22193369
-
Early assessment of subclinical myocardial injury in systemic lupus erythematosus by two-dimensional longitudinal layer speckle tracking imaging.Quant Imaging Med Surg. 2022 May;12(5):2947-2960. doi: 10.21037/qims-21-805. Quant Imaging Med Surg. 2022. PMID: 35502373 Free PMC article.
-
Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives.J Clin Med. 2023 Feb 9;12(4):1399. doi: 10.3390/jcm12041399. J Clin Med. 2023. PMID: 36835934 Free PMC article.
-
Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations.ACR Open Rheumatol. 2022 Jan;4(1):27-39. doi: 10.1002/acr2.11343. Epub 2021 Oct 17. ACR Open Rheumatol. 2022. PMID: 34658170 Free PMC article.
References
-
- Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T. et al.Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–2557. doi: 10.1002/art.21955. - DOI - PubMed
-
- Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 2004;31:713–719. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous